-
Versartis Inc (NASDAQ: VSAR) shares dipped 86
percent to $3.03 after the company disclosed that somavaratan did not meet primary endpoint in Phase 3 VELOCITY trial. Barclays
downgraded Versartis from Overweight to Underweight, while Cowen & Co. downgraded the stock from Outperform to Market Perform.
-
Revolution Lighting Technologies Inc (NASDAQ: RVLT) shares dropped 18.4 percent to $6.18 as the company lowered its FY2017
sales guidance.
-
SECOO HOLDING LTD (NASDAQ: SECO) shares slipped
15.5 percent to $10.99. Secoo Holding prices its IPO at $13 per ADS.
-
Intercept Pharmaceuticals Inc (NASDAQ: ICPT)
shares fell 14.4 percent to $63.13. Shares of Intercept Pharmaceuticals lost around one quarter of their value Thursday and
another 14 percent Friday in reaction to a concerning U.S. Food and Drug Administration letter sent to doctors regarding its
liver treatment product called Ocaliva for the treatment of primary biliary cholangitis. Citigroup downgraded Intercept
Pharmaceuticals from Buy to Neutral.
-
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC)
shares declined 13 percent to $1.95.
-
Exelixis, Inc. (NASDAQ: EXEL) shares dropped 12.8
percent to $24.42. Leerink Swann downgraded Exelixis from Outperform to Market Perform.
-
Abeona Therapeutics Inc (NASDAQ: ABEO) shares
declined 8.7 percent to $14.80.
-
Compass Minerals International, Inc. (NYSE: CMP)
shares fell 8.5 percent to $63.60 as the company lowered its FY17 earnings outlook.
-
Presidio Inc (NASDAQ: PSDO) declined 4.8 percent
to $13.28. Presidio reported in-line earnings for its fourth quarter, while sales missed estimates.
-
United States Steel Corporation (NYSE: X) shares
dropped 4 percent to $23.68. Cowen & Co. downgraded United States Steel from Market Perform to Underperform.
-
Carvana Co (NYSE: CVNA) fell 3.1 percent to $16.30.
B. Riley initiated coverage on Carvana with a Sell rating and a $12.00 price target.
-
Rambus Inc. (NASDAQ: RMBS) fell 2.3 percent to
$13.05. JP Morgan downgraded Rambus from Overweight to Neutral.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.